ClinicalTrials.Veeva

Menu

Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias (CAPID)

U

University Hospital of Bordeaux

Status

Not yet enrolling

Conditions

Connective Tissue Diseases
Interstitial Lung Disease

Treatments

Diagnostic Test: capillaroscopy

Study type

Interventional

Funder types

Other

Identifiers

NCT07283081
CHUBX 2025/086

Details and patient eligibility

About

The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.

Full description

Diffuse interstitial lung diseases (DILD) are a group of diseases characterized by inflammation and fibrosis of the lung tissue, with more than 200 identified causes, approximately 20% of which are related to autoimmune diseases such as connective tissue disorders (e.g., scleroderma, lupus). Pulmonary involvement may precede the diagnosis of connective tissue disease, making diagnosis difficult. Capillaroscopy, a non-invasive and reproducible test, is used to detect microvascular abnormalities, especially in scleroderma spectrum diseases, but its precise role in the evaluation of PID is still poorly defined. Studies show that PIDs associated with autoimmunity are more likely to present with capillaroscopic abnormalities. However, current recommendations on the investigation of PIDs do not clearly specify the use of capillaroscopy, and there are no studies establishing its value in systematic screening of all patients with PID. Thus the investigators aim to describe the characteristics of capillaroscopy in patients with a new diagnosis of PID.

The project will be offered to eligible patients for whom a PID has been identified. A review of the medical record information will then be carried out, with additional tests performed as necessary to identify the etiology associated with this IDP. The compilation of information, and especially the performance of additional tests (beyond normal care), is typically completed within three months. In the meantime, and particularly in the first month after signing the consent form, the patient will undergo a capillaroscopy and complete the patient questionnaire. After three months, once all additional tests have been performed and the results compiled, the pulmonologist completes the questionnaire to identify the most likely etiology of the patient's PID. All tests, except for capillaroscopy, are performed as part of routine care.

Enrollment

48 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female over 18 years of age;
  • Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;
  • Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP);
  • French-speaking patient with no comprehension difficulties;
  • Person affiliated with or beneficiary of a social security system;
  • Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).

Exclusion criteria

  • Have previously undergone a capillaroscopy, regardless of the reason;
  • Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;
  • Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy;
  • Pregnant or breastfeeding women;
  • Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent).

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

48 participants in 1 patient group

Diffuse interstitial lung diseases (DILD)
Experimental group
Treatment:
Diagnostic Test: capillaroscopy

Trial contacts and locations

1

Loading...

Central trial contact

Marie-Elise TRUCHETET, MD, PhD; Thomas BARNETCHE, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems